BioVectra Announces Oncolix Inc. Signs Manufacturing and Investment Agreement
CHARLOTTETOWN, PEI-(Business Wire)-September 23, 2009 - BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for human clinical testing. As part of this agreement, BioVectra will be investing $1.5 million in Oncolix. Prolanta is a targeted therapeutic protein under development for the treatment of breast and ovarian cancer.
BioVectra brings specific capabilities in recombinant protein fermentation, downstream processing, and process engineering to the partnership, in addition to a depth of experience and demonstrated track record in cGMP manufacturing of active pharmaceutical ingredients.
“This agreement exemplifies the value we offer the global biopharmaceutical industry, given our ability to undertake appropriate project management and stepwise scale-up in response to a client’s program requirements,” stated Dale Zajicek, Chief Operating Officer for BioVectra. “Prolanta is at an early stage of investigation, and Oncolix needed to identify a partner with a unique set of fermentation and downstream processing skills – who was also willing to customize a scale-up plan, efficiently and effectively under the required regulations.”
“We chose BioVectra as our contract manufacturer because of their ability to produce cGMP manufacturing of Prolanta from shaker flask, to small-scale to full commercial production,” said Michael Redman, CEO for Oncolix. “In addition, BioVectra has significant experience with FDA regulatory compliance.
About Oncolix
Oncolix is a biotechnology company focused on cancer. The company is developing a new breast and ovarian cancer drug (Prolanta) that targets the prolactin pathway. Because prolactin receptors are present in 90 percent and 60 percent of breast and ovarian cancer patients respectively, Prolanta has the potential to be used in combination with current therapies or in patients who fail therapy. Prolanta is currently in late stage preclinical development and a Phase I clinical trial is forecasted to commence in the 2nd quarter of 2010. Since inception in 2006, Oncolix has raised $8.0 million.
About BioVectra
BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients (API’s), pharmaceutical intermediates and bioprocess reagents. BioVectra currently holds nine DMF Filings and is an active supplier to many major companies in the pharmaceutical, and biotechnology industries.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
